These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23095029)

  • 1. Overview of recent drug discovery approaches for new generation leukotriene A4 hydrolase inhibitors.
    Calışkan B; Banoglu E
    Expert Opin Drug Discov; 2013 Jan; 8(1):49-63. PubMed ID: 23095029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton.
    Rao NL; Dunford PJ; Xue X; Jiang X; Lundeen KA; Coles F; Riley JP; Williams KN; Grice CA; Edwards JP; Karlsson L; Fourie AM
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1154-60. PubMed ID: 17371808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.
    Numao S; Hasler F; Laguerre C; Srinivas H; Wack N; Jäger P; Schmid A; Osmont A; Röthlisberger P; Houguenade J; Bergsdorf C; Dawson J; Carte N; Hofmann A; Markert C; Hardaker L; Billich A; Wolf RM; Penno CA; Bollbuck B; Miltz W; Röhn TA
    Sci Rep; 2017 Oct; 7(1):13591. PubMed ID: 29051536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationship studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A(4) (LTA(4)) hydrolase.
    Penning TD; Chandrakumar NS; Chen BB; Chen HY; Desai BN; Djuric SW; Docter SH; Gasiecki AF; Haack RA; Miyashiro JM; Russell MA; Yu SS; Corley DG; Durley RC; Kilpatrick BF; Parnas BL; Askonas LJ; Gierse JK; Harding EI; Highkin MK; Kachur JF; Kim SH; Krivi GG; Villani-Price D; Pyla EY; Smith WG
    J Med Chem; 2000 Feb; 43(4):721-35. PubMed ID: 10691697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukotriene A4 hydrolase: identification of a common carboxylate recognition site for the epoxide hydrolase and aminopeptidase substrates.
    Rudberg PC; Tholander F; Andberg M; Thunnissen MM; Haeggström JZ
    J Biol Chem; 2004 Jun; 279(26):27376-82. PubMed ID: 15078870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
    Grice CA; Tays KL; Savall BM; Wei J; Butler CR; Axe FU; Bembenek SD; Fourie AM; Dunford PJ; Lundeen K; Coles F; Xue X; Riley JP; Williams KN; Karlsson L; Edwards JP
    J Med Chem; 2008 Jul; 51(14):4150-69. PubMed ID: 18588282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thermodynamic properties of leukotriene A
    Wittmann SK; Kalinowsky L; Kramer JS; Bloecher R; Knapp S; Steinhilber D; Pogoryelov D; Proschak E; Heering J
    Bioorg Med Chem; 2016 Nov; 24(21):5243-5248. PubMed ID: 27651294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of leukotriene A4 (LTA4) hydrolase as potential anti-inflammatory agents.
    Penning TD
    Curr Pharm Des; 2001 Feb; 7(3):163-79. PubMed ID: 11311111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds.
    Sandanayaka V; Mamat B; Bhagat N; Bedell L; Halldorsdottir G; Sigthorsdottir H; Andrésson T; Kiselyov A; Gurney M; Singh J
    Bioorg Med Chem Lett; 2010 May; 20(9):2851-4. PubMed ID: 20371179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase.
    Chen Z; Wu Y; Liu Y; Yang S; Chen Y; Lai L
    J Med Chem; 2011 May; 54(10):3650-60. PubMed ID: 21542630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies.
    Kachur JF; Askonas LJ; Villani-Price D; Ghoreishi-Haack N; Won-Kim S; Liang CD; Russell MA; Smith WG
    J Pharmacol Exp Ther; 2002 Feb; 300(2):583-7. PubMed ID: 11805220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hybrid Receptor-Bound/MM-GBSA-Per-residue Energy-Based Pharmacophore Modelling: Enhanced Approach for Identification of Selective LTA4H Inhibitors as Potential Anti-inflammatory Drugs.
    Appiah-Kubi P; Soliman M
    Cell Biochem Biophys; 2017 Mar; 75(1):35-48. PubMed ID: 27914004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual anti-inflammatory and selective inhibition mechanism of leukotriene A4 hydrolase/aminopeptidase: insights from comparative molecular dynamics and binding free energy analyses.
    Appiah-Kubi P; Soliman ME
    J Biomol Struct Dyn; 2016 Nov; 34(11):2418-33. PubMed ID: 26555301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis.
    Sandanayaka V; Mamat B; Mishra RK; Winger J; Krohn M; Zhou LM; Keyvan M; Enache L; Sullins D; Onua E; Zhang J; Halldorsdottir G; Sigthorsdottir H; Thorlaksdottir A; Sigthorsson G; Thorsteinnsdottir M; Davies DR; Stewart LJ; Zembower DE; Andresson T; Kiselyov AS; Singh J; Gurney ME
    J Med Chem; 2010 Jan; 53(2):573-85. PubMed ID: 19950900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A(4) hydrolase.
    Penning TD; Chandrakumar NS; Desai BN; Djuric SW; Gasiecki AF; Liang CD; Miyashiro JM; Russell MA; Askonas LJ; Gierse JK; Harding EI; Highkin MK; Kachur JF; Kim SH; Villani-Price D; Pyla EY; Ghoreishi-Haack NS; Smith WG
    Bioorg Med Chem Lett; 2002 Dec; 12(23):3383-6. PubMed ID: 12419366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of benzofuran central cores for the inhibition of leukotriene A(4) hydrolase.
    Eccles W; Blevitt JM; Booker JN; Chrovian CC; Crawford S; de Leon AR; Deng X; Fourie AM; Grice CA; Herman K; Karlsson L; Kearney AM; Lee-Dutra A; Liang J; Luna R; Pippel D; Rao N; Riley JP; Santillán A; Savall B; Tanis VM; Xue X; Young AL
    Bioorg Med Chem Lett; 2013 Feb; 23(3):811-5. PubMed ID: 23260350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase I: in vitro studies.
    Askonas LJ; Kachur JF; Villani-Price D; Liang CD; Russell MA; Smith WG
    J Pharmacol Exp Ther; 2002 Feb; 300(2):577-82. PubMed ID: 11805219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase.
    Kirkland TA; Adler M; Bauman JG; Chen M; Haeggström JZ; King B; Kochanny MJ; Liang AM; Mendoza L; Phillips GB; Thunnissen M; Trinh L; Whitlow M; Ye B; Ye H; Parkinson J; Guilford WJ
    Bioorg Med Chem; 2008 May; 16(9):4963-83. PubMed ID: 18394906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase.
    Meng H; Liu Y; Zhai Y; Lai L
    Eur J Med Chem; 2013 Jan; 59():160-7. PubMed ID: 23220644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug discovery strategies for novel leukotriene A4 hydrolase inhibitors.
    Röhn TA; Numao S; Otto H; Loesche C; Thoma G
    Expert Opin Drug Discov; 2021 Dec; 16(12):1483-1495. PubMed ID: 34191664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.